Advances in cervical cancer: current insights and future directions

Abstract

In alignment with the World Health Organization’s strategy to eliminate cervical cancer, substantial progress has been made in the treatment of this malignancy. Cervical cancer, largely driven by human papillomavirus (HPV) infection, is considered preventable and manageable because of its well-established etiology. Advancements in precision screening technologies, such as DNA methylation triage, HPV integration detection, liquid biopsies, and artificial intelligence-assisted diagnostics, have augmented traditional screening methods such as HPV nucleic acid testing and cytology. Therapeutic strategies aimed at eradicating HPV and reversing precancerous lesions have been refined as pivotal measures for disease prevention. The controversy surrounding surgery for early-stage cervical cancer revolves around identifying optimal candidates for minimally invasive and conservative procedures without compromising oncological outcomes. Recent clinical trials have yielded promising results for the development of systemic therapies for advanced cervical cancer. Immunotherapies, such as immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), and targeted therapy have demonstrated significant effectiveness, marking a substantial advancement in cervical cancer management. Various combination therapies have been validated, and ongoing trials aim to enhance outcomes through the development of novel drugs and optimized combination regimens. The prospect of eradicating cervical cancer as the first malignancy to be eliminated is now within reach. In this review, we provide a comprehensive overview of the latest scientific insights, with a particular focus on precision managements for various stages of cervical disease, and explore future research directions in cervical cancer.

Keywords

cervical cancer / carcinogenesis / clinical trials / human papillomavirus / immunotherapy / precision medicine / screening strategies / targeted therapy / therapeutic advancements

References

[1] Organization WH. Cervical cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

[2] WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: Use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV). WHO Guidelines Approved by the Guidelines Review Committee. 2nd ed. Geneva: 2024.

[3] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.

[4] Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health. 2023; 8(12): e943–e955.

[5] Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond). 2023; 43(1): 75–86.

[6] Organization WH. HPV information center. 2024. Available from: https://hpvcentre.net/

[7] Pataky RE, Izadi-Najafabadi S. Smith LW, Gottschlich A, Ionescu D, Proctor L, et al. Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study. CMAJ. 2024; 196(21): E716–E723.

[8] Government A. Cervical cancer in Australia statistics 2022. Available from: https://www.canceraustralia.gov.au/cancer-types/cervical-cancer/statistics

[9] Rahangdale L, Teodoro N, Chinula L, Brewer NT. Eliminating cervical cancer as a global public health problem requires equitable action. BMJ. 2023; 383: 2978.

[10] Rahangdale L, Mungo C, O’Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022; 379: e070115.

[11] Alfaro K, Maza M, Cremer M, Masch R, Soler M. Removing global barriers to cervical cancer prevention and moving towards elimination. Nat Rev Cancer. 2021; 21(10): 607–608.

[12] Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020; 395(10224): 575–590.

[13] Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B. et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023; 11(2): e197–e206.

[14] UNAIDS. AIDSinfo 2023. Available from: https://aidsinfo.unaids.org/

[15] Dzinamarira T, Moyo E, Dzobo M, Mbunge E, Murewanhema G. Cervical cancer in sub-Saharan Africa: an urgent call for improving accessibility and use of preventive services. Int J Gynecol Cancer. 2023; 33(4): 592–597.

[16] Organization WH. Cancer Today 2022. Available from: https://gco.iarc.who.int/today/en

[17] Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021; 21(1): 894.

[18] Zhang M, Zhong Y, Bao H, Zhao Z, Huang Z, Zhang X, et al. Breast Cancer Screening Rates Among Women Aged 20 Years and Above -China, 2015. China CDC Wkly. 2021; 3(13): 267–273.

[19] Zhang M, Zhong Y, Zhao Z, Huang Z, Zhang X, Li C, et al. Cervical Cancer Screening Rates Among Chinese Women -China, 2015. China CDC Wkly. 2020; 2(26): 481–486.

[20] New government plan to speed up elimination of cervical cancer 2023. Available from: https://english.www.gov.cn/policies/policywatch/202302/08/content_WS63e30acdc6d0a757729e681d.html

[21] Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013; 382(9895): 889–899.

[22] Guan P, Howell-Jones R. Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012; 131(10): 2349–2359.

[23] Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical Cancer Screening: A Review. JAMA. 2023; 330(6): 547–558.

[24] Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: A growing global problem. Int J Appl Basic Med Res. 2016; 6(2): 84–89.

[25] Voelker RA. Cervical Cancer Screening. JAMA. 2023; 330(20): 2030.

[26] Markowitz LE, Unger ER. Human Papillomavirus Vaccination. N Engl J Med. 2023; 388(19): 1790–1798.

[27] Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 2011; 19(1): 33–39.

[28] Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020; 70(5): 321–346.

[29] Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019; 393(10167): 169–182.

[30] Li XY, Li G, Gong TT, Lv JL, Gao C, Liu FH, et al. Non-Genetic Factors and Risk of Cervical Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies. Int J Public Health. 2023; 68: 1605198.

[31] Bhat D. The ‘Why and How’ of Cervical Cancers and Genital HPV Infection. Cytojournal. 2022; 19: 22.

[32] Hu K, Wang J, Sparen P, Herweijer E, Sjolander A, Adami HO, et al. Invasive cervical cancer, precancerous lesions, and cervical screening participation among women with mental illness in Sweden: a population-based observational study. Lancet Public Health. 2023; 8(4): e266–e275.

[33] Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007; 212(4): 356–367.

[34] zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2(5): 342–350.

[35] Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010; 10(8): 550–560.

[36] Hu Z, Zhu D, Wang W, Li W, Jia W, Zeng X, et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet. 2015; 47(2): 158–163.

[37] Huang J, Qian Z, Gong Y, Wang Y, Guan Y, Han Y, et al. Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning. J Med Genet. 2019; 56(3): 186–194.

[38] Fan J, Fu Y, Peng W, Li X, Shen Y, Guo E, et al. Multi-omics characterization of silent and productive HPV integration in cervical cancer. Cell Genom. 2023; 3(1): 100211.

[39] Bi Y, Hu J, Zeng L, Chen G, Cai H, Cao H, et al. Characteristics of HPV integration in cervical adenocarcinoma and squamous carcinoma. J Cancer Res Clin Oncol. 2023; 149(20): 17973–17986.

[40] Cancer Genome Atlas Research N, Albert Einstein College of M, Analytical Biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017; 543(7645): 378–384.

[41] Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008; 68(1): 307–313.

[42] McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog. 2017; 13(4): e1006211.

[43] Zhou L, Qiu Q, Zhou Q, Li J, Yu M, Li K, et al. Long-read sequencing unveils high-resolution HPV integration and its oncogenic progression in cervical cancer. Nat Commun. 2022; 13(1): 2563.

[44] Peng Q, Wang L, Zuo L, Gao S, Jiang X, Han Y, et al. HPV E6/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor. Cancer Gene Ther. 2024; 31(1): 9–17.

[45] Baedyananda F, Sasivimolrattana T, Chaiwongkot A, Varadarajan S, Bhattarakosol P. Role of HPV16 E1 in cervical carcinogenesis. Front Cell Infect Microbiol. 2022; 12: 955847.

[46] Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014; 111(43): 15544–15549.

[47] Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, et al. HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. Mol Cancer Res. 2018; 16(1): 90–102.

[48] Molina MA, Steenbergen RDM, Pumpe A, Kenyon AN, Melchers WJG. HPV integration and cervical cancer: a failed evolutionary viral trait. Trends Mol Med. 2024; 30(9): 890–902.

[49] Rusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus-associated cancers. Clin Cancer Res. 2015; 21(9): 2009–2019.

[50] Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I. Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014; 506(7488): 371–375.

[51] Mallick S, Choi Y, Taylor AM, Cosper PF. Human Papillomavirus-Induced Chromosomal Instability and Aneuploidy in Squamous Cell Cancers. Viruses. 2024; 16(4): 501.

[52] Thorland EC, Myers SL, Persing DH, Sarkar G, McGovern RM, Gostout BS, et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res. 2000; 60(21): 5916–5921.

[53] Hatano T, Sano D, Takahashi H, Oridate N. Pathogenic Role of Immune Evasion and Integration of Human Papillomavirus in Oropharyngeal Cancer. Microorganisms. 2021; 9(5): 891.

[54] Cao C, Xu Q, Zhu Z, Xu M, Wei Y, Lin S, et al. Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer. Cancer Lett. 2024; 588: 216809.

[55] Liu H, Ma H, Li Y, Zhao H. Advances in epigenetic modifications and cervical cancer research. Biochim Biophys Acta Rev Cancer. 2023; 1878(3): 188894.

[56] Li L, Yang WT, Zheng PS, Liu XF. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/beta-catenin signaling pathway via trans-suppressing beta-catenin in cervical cancer. Cell Death Dis. 2018; 9(7): 741.

[57] Kremer WW, Van Zummeren M, Novianti PW, Richter KL, Verlaat W, Snijders PJ, et al. Detection of hypermethylated genes as markers for cervical screening in women living with HIV. J Int AIDS Soc. 2018; 21(8): e25165.

[58] Chang CL, Ho SC, Su YF, Juan YC, Huang CY, Chao AS, et al. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan. Gynecol Oncol. 2021; 161(2): 429–435.

[59] Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, et al. Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women. Clin Cancer Res. 2018; 24(9): 2194–2202.

[60] Verlaat W, Van Leeuwen RW, Novianti PW, Schuuring E, Meijer C, Van Der Zee AGJ, et al. Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer. Epigenetics. 2018; 13(7): 769–778.

[61] Lai Y, He Z, Zhang A, Yan Z, Zhang X, Hu S, et al. Tip60 and p300 function antagonistically in the epigenetic regulation of HPV18 E6/E7 genes in cervical cancer HeLa cells. Genes Genomics. 2020; 42(6): 691–698.

[62] Johansson C, Jamal Fattah T, Yu H, Nygren J, Mossberg AK, Schwartz S. Acetylation of intragenic histones on HPV16 correlates with enhanced HPV16 gene expression. Virology. 2015; 482: 244–259.

[63] Chakraborty S, Das K, Saha S, Mazumdar M, Manna A, Chakraborty S, et al. Nuclear matrix protein SMAR1 represses c-Fos-mediated HPV18 E6 transcription through alteration of chromatin histone deacetylation. J Biol Chem. 2014; 289(42): 29074–29085.

[64] Dooley KE, Warburton A, McBride AA. Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes. mBio. 2016; 7(5): e01446–16.

[65] Warburton A, Markowitz TE, Katz JP, Pipas JM, McBride AA. Recurrent integration of human papillomavirus genomes at transcriptional regulatory hubs. NPJ Genom Med. 2021; 6(1): 101.

[66] Shen S, Zhang S, Liu P, Wang J, Du H. Potential role of microRNAs in the treatment and diagnosis of cervical cancer. Cancer Genet. 2020; 248-249: 25–30.

[67] Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022; 19(3): 188–206.

[68] Kim HJ, Lee DW, Yim GW, Nam EJ, Kim S, Kim SW, et al. Long non-coding RNA HOTAIR is associated with human cervical cancer progression. 2014. Available from:

[69] Sharma S, Munger K. Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling. mBio. 2020; 11(3): e01190–20.

[70] Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012; 485(7398): 376–380.

[71] Cao C, Xu Q, Lin S, Zhi W, Lazare C, Meng Y, et al. Mapping long-range contacts between risk loci and target genes in human diseases with Capture Hi-C. Clin Transl Med. 2020; 10(5): e183.

[72] Cao C, Hong P, Huang X, Lin D, Cao G, Wang L, et al. HPV-CCDC106 integration alters local chromosome architecture and hijacks an enhancer by three-dimensional genome structure remodeling in cervical cancer. J Genet Genomics. 2020; 47(8): 437–450.

[73] Tian R, Huang Z, Li L, Yuan J, Zhang Q, Meng L, et al. HPV integration generates a cellular super-enhancer which functions as ecDNA to regulate genome-wide transcription. Nucleic Acids Res. 2023; 51(9): 4237–4251.

[74] Rosendo-Chalma P, Antonio-Vejar V. Ortiz Tejedor JG, Ortiz Segarra J, Vega Crespo B, Bigoni-Ordonez GD. The Hallmarks of Cervical Cancer: Molecular Mechanisms Induced by Human Papillomavirus. Biology (Basel). 2024; 13(2): 77.

[75] Shi Y, Li L, Hu Z, Li S, Wang S, Liu J, et al. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12. Nat Genet. 2013; 45(8): 918–922.

[76] Bowden SJ, Bodinier B, Kalliala I, Zuber V, Vuckovic D, Doulgeraki T, et al. Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study. Lancet Oncol. 2021; 22(4): 548–557.

[77] Al-Harbi NM, Bin Judia SS, Mishra KN, Shoukri MM, Alsbeih GA. Genetic Predisposition to Cervical Cancer and the Association With XRCC1 and TGFB1 Polymorphisms. Int J Gynecol Cancer. 2017; 27(9): 1949–1956.

[78] Takeuchi F, Kukimoto I, Li Z, Li S, Li N, Hu Z, et al. Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection. Hum Mol Genet. 2019; 28(2): 341–348.

[79] Wang SS, Bratti MC, Rodriguez AC, Herrero R, Burk RD, Porras C, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009; 199(1): 20–30.

[80] Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U. et al. Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study. PLoS Genet. 2017; 13(8): e1006866.

[81] Ivansson EL, Juko-Pecirep I. Erlich HA, Gyllensten UB. Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPB1 affects risk in Swedish women. Genes Immun. 2011; 12(8): 605–614.

[82] Society AC. Cancer Statistics Center. 2024. Available from: https://cancerstatisticscenter.cancer.org/

[83] Golia D’Augè T, Cuccu I, Etrusco A, D’Amato A, Laganà AS, D’Oria O, et al. State of the art on HPV-related cervical lesions. Italian Journal of Gynaecology and Obstetrics. 2024; 36(02): 135–137.

[84] Organization WH. Global strategy to accelerate the elimination of cervical cancer as a public health problem 2020. Available from: https://www.who.int/publications-detail-redirect/9789240014107

[85] Clark M, Jembere N, Kupets R. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts. Prev Med. 2021; 150: 106641.

[86] Bogani G, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, Vercellini P, et al. HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of vaccination. Tumori. 2024; 110(2): 139–145.

[87] Organization WH. Human papillomavirus vaccines: WHO position paper, December 2022. 2022. Available from: https://www.who.int/publications/i/item/who-wer9750-645-672

[88] Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P. et al. The IARC Perspective on Cervical Cancer Screening. N Engl J Med. 2021; 385(20): 1908–1918.

[89] Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298(7): 743–753.

[90] Gavinski K, DiNardo D. Cervical Cancer Screening. Med Clin North Am. 2023; 107(2): 259–269.

[91] Demarco M, Egemen D, Hyun N, Chen X, Moscicki AB, Cheung L, et al. Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus-Positive Screening Test Results. J Low Genit Tract Dis. 2022; 26(2): 127–134.

[92] Force USPST, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 320(7): 674–686.

[93] Derbie A, Mekonnen D, Woldeamanuel Y, Van Ostade X, Abebe T. HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review. Infect Agent Cancer. 2020; 15: 9.

[94] Wright TC, Jr., Stoler MH, Ranger-Moore J. Fang Q, Volkir P, Safaeian M, et al. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial. Int J Cancer. 2022; 150(3): 461–471.

[95] Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, et al. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncol. 2019; 5(2): 181–186.

[96] Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. JAMA Intern Med. 2019; 179(7): 881–888.

[97] Mishra S, Awasthi NP, Husain N, Anand A, Pradeep Y, Ansari R, et al. Flow Cytometric Analysis of DNA Ploidy in Liquid Based Cytology for Cervical Pre-Cancer and Cancer. Asian Pac J Cancer Prev. 2017; 18(6): 1595–1601.

[98] Kong L, Wang L, Wang Z, Xiao X, You Y, Wu H, et al. Cytological DNA methylation for cervical cancer screening: a validation set. Front Oncol. 2023; 13: 1181982.

[99] Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022; 10(8): e1115–e1127.

[100] Zhao XL, Zhao S, Xia CF, Hu SY, Duan XZ, Liu ZH, et al. Cost-effectiveness of the screen-and-treat strategies using HPV test linked to thermal ablation for cervical cancer prevention in China: a modeling study. BMC Med. 2023; 21(1): 149.

[101] Pretsch PK, Spees LP, Brewer NT, Hudgens MG, Sanusi B, Rohner E, et al. Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial. Lancet Public Health. 2023; 8(6): e411–e421.

[102] Fan C, Ma Q, Wu X, Dai X, Peng Q, Cai H. Detection of DNA Methylation in Gene Loci ASTN1, DLX1, ITGA4, RXFP3, SOX17, and ZNF671 for Diagnosis of Cervical Cancer. Cancer Manag Res. 2023; 15: 635–644.

[103] Li L. Novel methylated genes as a second triage step after hrHPV testing to improve colposcopy referral in HPV infected women with cervical lesions (cancer). Int J Gynecol Cancer. 2022; 32: A408–A409.

[104] Wang Y, Chuan J, Zhu B, Zu Y, Zhang R, Tang L, et al. Evaluation of PAX1/ST6GALNAC5 methylation as a triage test for cervical intraepithelial neoplasia and cervical cancer. Epigenomics. 2023; 15(3): 131–145.

[105] Schreiberhuber L, Barrett JE, Wang J, Redl E, Herzog C, Vavourakis CD, et al. Cervical cancer screening using DNA methylation triage in a real-world population. Nat Med. 2024; 30(8): 2251–2257.

[106] Hu T, Li K, He L, Huang F, Yang F, Chen S, et al. Testing for viral DNA integration among HPV-positive women to detect cervical precancer: An observational cohort study. BJOG. 2024; 131(3): 309–318.

[107] Carreon JD, Sherman ME, Guillen D, Solomon D, Herrero R, Jeronimo J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007; 26(4): 441–446.

[108] Wang J, Yu Y, Tan Y, Wan H, Zheng N, He Z, et al. Artificial intelligence enables precision diagnosis of cervical cytology grades and cervical cancer. Nat Commun. 2024; 15(1): 4369.

[109] Herbst J, Pantel K, Effenberger K, Wikman H. Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions. Br J Cancer. 2022; 127(8): 1403–1410.

[110] Cafforio P, Palmirotta R, Lovero D, Cicinelli E, Cormio G, Silvestris E, et al. Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls. Cancers (Basel). 2021; 13(16): 3968.

[111] Sivars L, Palsdottir K, Crona Guterstam Y, Falconer H, Hellman K, Tham E. The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review. Int J Cancer. 2023; 152(11): 2232–2242.

[112] Leffers M, Herbst J, Kropidlowski J, Prieske K, Bohnen AL, Peine S, et al. Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients. Cancers (Basel). 2022; 14(16): 3954.

[113] Sivars L, Hellman K, Crona Guterstam Y, Holzhauser S, Nordenskjold M, Falconer H, et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer. Gynecol Oncol. 2022; 167(1): 107–114.

[114] Han K, Zou J, Zhao Z, Baskurt Z, Zheng Y, Barnes E, et al. Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer. J Clin Oncol. 2024; 42(4): 431–440.

[115] Tian X, Ge D, Zhang F, Zhang B, Bai W, Xu X, et al. Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. Int J Cancer. 2021; 148(4): 921–931.

[116] Wen YF, Cheng TT, Chen XL, Huang WJ, Peng HH, Zhou TC, et al. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. PLoS One. 2018; 13(10): e0204334.

[117] Du K, Huang Q, Bu J, Zhou J, Huang Z, Li J. Circulating Tumor Cells Counting Act as a Potential Prognostic Factor in Cervical Cancer. Technol Cancer Res Treat. 2020; 19: 1533033820957005.

[118] Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, et al. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020; 19(11): 2363–2370.

[119] Sun W, Wang L, Zhao D, Wang P, Li Y, Wang S. Four Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting Cervical Cancer. Gynecol Obstet Invest. 2018; 83(6): 533–539.

[120] Du S, Zhao Y, Lv C, Wei M, Gao Z, Meng X. Applying Serum Proteins and MicroRNA as Novel Biomarkers for Early-Stage Cervical Cancer Detection. Sci Rep. 2020; 10(1): 9033.

[121] Zheng M, Hou L, Ma Y, Zhou L, Wang F, Cheng B, et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer. 2019; 18(1): 76.

[122] Sargent A, Fletcher S, Bray K, Kitchener HC, Crosbie EJ. Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening. BMJ Open. 2019; 9(4): e025388.

[123] Shih YH, Sun L, Hsu ST, Chen MJ, Lu CH. Can HPV Test on Random Urine Replace Self-HPV Test on Vaginal Self-Samples or Clinician-Collected Cervical Samples? Int J Womens Health. 2023; 15: 1421–1429.

[124] Frazer IH, Leggatt GR, Mattarollo SR. Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol. 2011; 29: 111–138.

[125] WHO Guidelines: Use of Cryotherapy for Cervical Intraepithelial Neoplasia. WHO Guidelines Approved by the Guidelines Review Committee. Geneva: 2011.

[126] Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020; 24(2): 102–131.

[127] Papalia N, Rohla A, Tang S, Nation J, Nelson G. Defining the short-term disease recurrence after loop electrosurgical excision procedure (LEEP). BMC Womens Health. 2020; 20(1): 34.

[128] D’Alessandro P, Arduino B, Borgo M, Saccone G, Venturella R, Di Cello A, et al. Loop Electrosurgical Excision Procedure versus Cryotherapy in the Treatment of Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Gynecol Minim Invasive Ther. 2018; 7(4): 145–151.

[129] Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Ghezzi F, et al. HPV persistence after cervical surgical excision of high-grade cervical lesions. Cancer Cytopathol. 2024; 132(5): 268–269.

[130] Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2020; 24(2): 132–143.

[131] Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Giannini A, et al. Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. Eur J Cancer Prev. 2023; 32(6): 525–532.

[132] Mix J, Saraiya M, Hallowell BD, Befano B, Cheung LC, Unger ER, et al. Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. J Natl Cancer Inst. 2022; 114(6): 845–853.

[133] Istomin YP, Lapzevich TP, Chalau VN, Shliakhtsin SV, Trukhachova TV. Photodynamic therapy of cervical intraepithelial neoplasia grades II and III with Photolon. Photodiagnosis Photodyn Ther. 2010; 7(3): 144–151.

[134] Gu L, Cheng M, Hong Z, Di W, Qiu L. The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. Photodiagnosis Photodyn Ther. 2021; 33: 102172.

[135] Inada NM, Buzza HH, Leite MFM, Kurachi C, Trujillo JR, de Castro CA, et al. Long Term Effectiveness of Photodynamic Therapy for CIN Treatment. Pharmaceuticals (Basel). 2019; 12(3): 107.

[136] Wen X, Li Y, Hamblin MR. Photodynamic therapy in dermatology beyond non-melanoma cancer: An update. Photodiagnosis Photodyn Ther. 2017; 19: 140–152.

[137] Wang B, Su Y, Zhang C, Zhou M, Yuan S, Zhang M, et al. The effect of local photodynamic therapy with 5-aminolevulinic acid in treating different grades of cervical intraepithelial neoplasia. Photodiagnosis Photodyn Ther. 2022; 40: 103196.

[138] Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008; 8(5): 351–360.

[139] INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-base. HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18. 2021.

[140] INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-base. Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18 2021. Available from: https://www.prnewswire.com/news-releases/inovio-highlights-key-updates-on-phase-3-program-for-vgx-3100-its-dna-based-immunotherapy-for-the-treatment-of-cervical-hsil-caused-by-hpv-16-andor-hpv-18-301443997.html

[141] Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020; 8(3): 391.

[142] Wu P, Ma D, Wu P. Oncogenic virus integration: Moving toward clinical applications. Med. 2023; 4(6): 347–352.

[143] Gao C, Wu P, Yu L, Liu L, Liu H, Tan X, et al. The application of CRISPR/Cas9 system in cervical carcinogenesis. Cancer Gene Ther. 2022; 29(5): 466–474.

[144] Ling K, Yang L, Yang N, Chen M, Wang Y, Liang S, et al. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer. Hum Gene Ther. 2020; 31(5-6): 297–308.

[145] Niu G, Jin Z, Zhang C, He D, Gao X, Zou C, et al. An effective vaginal gel to deliver CRISPR/Cas9 system encapsulated in poly (beta-amino ester) nanoparticles for vaginal gene therapy. EBioMedicine. 2020; 58: 102897.

[146] Zhen S, Lu JJ, Wang LJ, Sun XM, Zhang JQ, Li X, et al. In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line. Transl Oncol. 2016; 9(6): 498–504.

[147] Tian R, Liu J, Fan W, Li R, Cui Z, Jin Z, et al. Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6/E7 genes in cervical cancer cells. Mol Ther Oncolytics. 2022; 24: 171–179.

[148] Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest. 2015; 125(1): 425–436.

[149] Ding W, Hu Z, Zhu D, Jiang X, Yu L, Wang X, et al. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells. Clin Cancer Res. 2014; 20(24): 6495–6503.

[150] Wenzel HHB, Smolders RGV, Beltman JJ, Lambrechts S, Trum HW, Yigit R, et al. Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review. Eur J Cancer. 2020; 133: 14–21.

[151] Song YL, Li RZ, Feng BJ, Lu YH, Wang LF, Wang ZY, et al. Survival after minimally invasive radical hysterectomy with protective colpotomy for early-stage cervical cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2024; 50(4): 108240.

[152] Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018; 379(20): 1895–1904.

[153] Ramirez PT, Robledo KP, Frumovitz M, Pareja R, Ribeiro R, Lopez A, et al. LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. J Clin Oncol. 2024:JCO2302335.

[154] Melamed A, Margul DJ, Chen L, Keating NL, Del Carmen MG, Yang J, et al. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med. 2018; 379(20): 1905–1914.

[155] Nitecki R, Ramirez PT, Frumovitz M, Krause KJ, Tergas AI, Wright JD, et al. Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020; 6(7): 1019–1027.

[156] Lewicki PJ, Basourakos SP, Qiu Y, Hu JC, Sheyn D, Hijaz A, et al. Effect of a Randomized, Controlled Trial on Surgery for Cervical Cancer. N Engl J Med. 2021; 384(17): 1669–1671.

[157] Zhu H, Yan Y, Liu Y, Meng L. The Impact of Minimally Invasive Surgery on Treating Patients with Early Cervical Adenocarcinoma. J Invest Surg. 2022; 35(7): 1593–1601.

[158] Frumovitz M, Obermair A, Coleman RL, Pareja R, Lopez A, Ribero R, et al. Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2020; 21(6): 851–860.

[159] Bogani G, Donato VD, Scambia G, Landoni F, Ghezzi F, Muzii L, et al. Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer. Gynecol Oncol. 2022; 166(3): 561–566.

[160] Vazquez-Vicente D, Boria F, Castellanos T, Gutierrez M, Chacon E, Manzour N, et al. SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer. Int J Gynecol Cancer. 2024; 34(2): 203–208.

[161] Guo C, Tang X, Meng Y, Zhang Y, Zhang X, Guo J, et al. Effect of the surgical approach on survival outcomes in patients undergoing radical hysterectomy for cervical cancer: A real-world multicenter study of a large Chinese cohort from 2006 to 2017. Cancer Med. 2020; 9(16): 5908–5921.

[162] Piedimonte S, Pond GR, Plante M, Nelson G, Kwon J, Altman A, et al. Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study. Gynecol Oncol. 2022; 166(2): 230–235.

[163] Paik ES, Lim MC, Kim MH, Kim YH, Song ES, Seong SJ, et al. Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028). Gynecol Oncol. 2019; 154(3): 547–553.

[164] Uppal S, Gehrig PA, Peng K, Bixel KL, Matsuo K, Vetter MH, et al. Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. J Clin Oncol. 2020; 38(10): 1030–1040.

[165] Leitao MM, Jr., Zhou QC, Brandt B, Iasonos A, Sioulas V, Lavigne Mager K, et al. The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecol Oncol. 2022; 166(3): 417–424.

[166] Kim NR, Kim SI, Suh DH, Kim HS, Kim K, Chung HH, et al. Survival outcomes of laparoscopic versus open radical hysterectomy in early cervical cancer with incidentally identified high-risk factors. Gynecol Oncol. 2023; 174: 224–230.

[167] Di Donato V, Bogani G, Casarin J, Ghezzi F, Malzoni M, Falcone F, et al. Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for “low-risk” early-stage cervical cancer: A propensity-score based analysis. Gynecol Oncol. 2023; 174: 49–54.

[168] Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer -Update 2023. Int J Gynecol Cancer. 2023; 33(5): 649–666.

[169] Giannini A, D’Oria O, Chiantera V, Margioula-Siarkou C. Di Donna MC, Terzic S, et al. Minimally Invasive Surgery for Cervical Cancer: Should We Look beyond Squamous Cell Carcinoma? J Invest Surg. 2022; 35(7): 1602–1603.

[170] Xu M, Huo C, Huang C, Wu B, Liu Y, Li J, et al. Feasibility of the “Cuff-Sleeve” Suture Method for Functional Neocervix Reconstruction in Laparoscopic Radical Trachelectomy: A Retrospective Analysis. J Minim Invasive Gynecol. 2022; 29(5): 673–682.

[171] Ding B, Guan X, Duan K, Shen Y. Laparoscopic radical hysterectomy with enclosed colpotomy without the use of uterine manipulator for early-stage cervical cancer. J Minim Access Surg. 2021; 17(4): 570–572.

[172] He F, Yuan S, Chen X, Zhang S, Han Y, Lin T, et al. Effect of modified no-touch laparoscopic radical hysterectomy on outcomes of early stage cervical cancer: A retrospective cohort study. Cancer Med. 2022; 11(11): 2224–2232.

[173] Jing H, Ran X, Li Z. Application of novel tumor-free techniques in laparoscopic radical hysterectomy for early cervical cancer. Asian J Surg. 2021; 44(8): 1069–1072.

[174] Kondo E, Yoshida K, Kubo-Kaneda M. Nii M, Okamoto K, Magawa S, et al. Does Vaginal Cuff Creation and Avoidance of a Uterine Manipulator Improve the Prognosis of Total Laparoscopic Radical Hysterectomy for Early Cervical Cancer? A Retrospective Multicenter Study. Cancers (Basel). 2022; 14(18): 4389.

[175] Kanao H, Matsuo K, Aoki Y, Tanigawa T, Nomura H, Okamoto S, et al. Feasibility and outcome of total laparoscopic radical hysterectomy with no-look no-touch technique for FIGO IB1 cervical cancer. J Gynecol Oncol. 2019; 30(3): e71.

[176] Kita M, Butsuhara Y, Hisamatsu Y, Yokoe T, Okada H. Pneumovaginoscopy-assisted radical hysterectomy for early-stage cervical cancer: a novel bidirectional approach for tumor spillage prevention and R0 resection. J Gynecol Oncol. 2023; 34(6): e80.

[177] Wu X, Yu H, Bai Y, Hou Y, Lou W, Wang X, et al. A multicenter noninferior randomized controlled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stage IB3 and IIA2): study protocol of the LAUNCH 3 trial. Trials. 2023; 24(1): 542.

[178] Wu X, Qiu L, Lou W, Wang X, Zhu T, Zhang Y, et al. A multicenter non-inferior randomized controlled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stages IB1, IB2, and IIA1): study protocol of the LAUNCH 2 trial. Trials. 2022; 23(1): 269.

[179] Hu TWY, Huang Y, Li N, Nie D, Li Z. Comparison of laparoscopic versus open radical hysterectomy in patients with early-stage cervical cancer: a multicenter study in China. Int J Gynecol Cancer. 2020; 30(8): 1143–1150.

[180] Yin Z, Cui Z, Kang S, Ji M, Li D, Chen B, et al. Laparoscopic versus open radical hysterectomy in FIGO 2018 early-stage cervical adenocarcinoma: Long-term survival outcomes after propensity score matching. J Obstet Gynaecol Res. 2023; 49(12): 2849–2859.

[181] Schaafsma M, Plante M, Mom CH, van Trommel NE. Is less more in the surgical treatment of early-stage cervical cancer? Curr Opin Oncol. 2022; 34(5): 473–489.

[182] Morice P, Maulard A, Scherier S, Sanson C, Zarokian J, Zaccarini F, et al. Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review. Gynecol Oncol. 2022; 165(1): 169–183.

[183] Batman SH, Schmeler KM. Fertility-Sparing and Less Radical Surgery for Cervical Cancer. Curr Oncol Rep. 2022; 24(11): 1541–1548.

[184] Schmeler KM, Pareja R, Lopez Blanco A, Humberto Fregnani J, Lopes A, Perrotta M, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021; 31(10): 1317–1325.

[185] Plante M, Kwon JS, Ferguson S, Samouelian V, Ferron G, Maulard A, et al. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. N Engl J Med. 2024; 390(9): 819–829.

[186] Carneiro VCG, Batista TP, Andrade MR, Barros AV, Camara L, Ramalho NM, et al. Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer </= 2 cm (LESSER). Int J Gynecol Cancer. 2023; 33(4): 498–503.

[187] Abu-Rustum NR. ConCerv: a prospective trial of conservative surgery for low-risk early stage cervical cancer, by Schmeler et al. Int J Gynecol Cancer. 2021; 31(10): 1326–1327.

[188] Bianchi T, Grassi T, Bazzurini L, Di Martino G, Negri S, Fruscio R, et al. Radical Hysterectomy in Early-Stage Cervical Cancer: Abandoning the One-Fits-All Concept. J Pers Med. 2023; 13(9): 1292.

[189] Park JY. Is it time to change surgery for early-stage low-risk cervical cancer to simple hysterectomy? J Gynecol Oncol. 2024; 35(2): e47.

[190] Benseler A, Covens A. Simple hysterectomy SHAPE-ing up to be the treatment of choice for early cervical cancer under 2 cm. J Gynecol Oncol. 2024; 35(2): e49.

[191] Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8): 734–743.

[192] Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A. Colombo N, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv72–iv83.

[193] Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004; 22(16): 3340–3344.

[194] Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009; 27(28): 4649–4655.

[195] Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340(15): 1137–1143.

[196] McCormack M, Gallardo Rincón D, Eminowicz G, Diez P, Farrelly L, Kent C, et al. A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial. Annals of Oncology. 2023; 34: S1276.

[197] Li F, Mei F, Yin S, Du Y, Hu L, Hong W, et al. Improving the efficacy and safety of concurrent chemoradiotherapy by neoadjuvant chemotherapy: a randomized controlled study of locally advanced cervical cancer with a large tumor. J Gynecol Oncol. 2024; 35(1): e10.

[198] Tripathi A, Rawat S. Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix. J Obstet Gynaecol India. 2019; 69(6): 546–552.

[199] Li J, Li Y, Wang H, Shen L, Wang Q, Shao S, et al. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer. BMC Cancer. 2023; 23(1): 51.

[200] da Costa SCS, Bonadio RC, Gabrielli FCG, Aranha AS, Dias Genta MLN, Miranda VC, et al. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial. J Clin Oncol. 2019; 37(33): 3124–3131.

[201] Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023; 24(5): 468–482.

[202] Kenter GG, Greggi S, Vergote I, Katsaros D, Kobierski J, van Doorn H, et al. Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994. J Clin Oncol. 2023; 41(32): 5035–5043.

[203] Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018; 36(16): 1548–1555.

[204] Feng X, Meng X, Tang D, Guo S, Liao Q, Chen J, et al. Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer. Cancer Pathog Ther. 2024; 2(1): 38–49.

[205] Li K, Chen J, Hu Y, Wang YZ, Shen Y, Chen G, et al. Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024; 25(1): 76–85.

[206] Fan J, Lu F, Qin T, Peng W, Zhuang X, Li Y, et al. Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance. Nat Genet. 2023; 55(12): 2175–2188.

[207] Liu W SJ, Liu R, et al. Neoadjuvant tislelizumab plus chemotherapy in patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial. SGO. 2024.

[208] Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017; 390(10103): 1654–1663.

[209] Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN Guidelines(R) Insights: Cervical Cancer, Version 1.2024. J Natl Compr Canc Netw. 2023; 21(12): 1224–1233.

[210] Suzuki K, Nagao S, Shibutani T, Yamamoto K, Jimi T, Yano H, et al. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. Gynecol Oncol. 2019; 154(3): 554–557.

[211] Schefter T, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014; 88(1): 101–105.

[212] Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020; 30(5): 596–601.

[213] Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phas. 2 trial. Lancet Oncol. 2015; 16(15): 1515–1524.

[214] Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidi AL, Papadaki A, et al. Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. Cancers (Basel). 2020; 12(11): 3145.

[215] Zhang L, Chen L, Yu H. Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-lin. treatment for recurrent or advanced cervical cancer patients. Invest New Drugs. 2020; 38(4): 1186–1191.

[216] Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, et al. The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019; 153(3): 535–540.

[217] Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, et al. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019; 154(1): 95–101.

[218] Montor WR, Salas A, Melo FHM. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Mol Cancer. 2018; 17(1): 55.

[219] Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480(7378): 480–489.

[220] Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023; 20(6): 359–371.

[221] Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1): 24–34.

[222] Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023; 8(1): 320.

[223] Monk BJ, Enomoto T, Kast WM, McCormack M, Tan DSP, Wu X, et al. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. Cancer Treat Rev. 2022; 106: 102385.

[224] Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022; 386(6): 544–555.

[225] Frenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA. Gomez-Roca C, et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017; 35(36): 4035–4041.

[226] Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acost. A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020; 38(1): 1–10.

[227] Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019; 37(31): 2825–2834.

[228] O’Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021; 163(2): 274–280.

[229] Xia L, Wang J, Wang C, Zhang Q, Zhu J, Rao Q, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. Int J Gynecol Cancer. 2023; 33(12): 1861–1868.

[230] Da Silva DM, Enserro DM, Mayadev JS, Skeate JG, Matsuo K, Pham HQ, et al. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020; 26(21): 5621–5630.

[231] Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R. et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019; 37(17): 1470–1478.

[232] Liu J LN, Wang D, Li D, Fang C. Efficacy and safety of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced cervical cancer: Cohort data from a phase 1b trial. J Clin Oncol. 2022; 40(16): 5535.

[233] Chen JYH, Fan R, Liu L, Xiao W, Lin R, Chen D, et al. Cadonilimab safety and efficacy in recurrent or metastatic cervical cancer: First real-world experience from a Chinese multicenter study. Journal of Clinical Oncology. 2024; 42(16): e17510.

[234] Wu XJJ, Lou H, Li Y, Feng M, Xu N, Li Y, et al. Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial Gynecologic Oncology. 2022; 166: S47–S48.

[235] Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R. et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021; 385(20): 1856–1867.

[236] Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023; 41(36): 5505–5511.

[237] Wang Y, Zhao J, Liang H, Liu J, Huang S, Zou G, et al. Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial. EClinicalMedicine. 2023; 65: 102274.

[238] An J, Li X, Wang J, Zhu L, An R, Jiang K, et al. Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study. Front Immunol. 2023; 14: 1142256.

[239] Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024; 403(10434): 1341–1350.

[240] Monk BJ, Toita T, Wu X, Vazquez Limon JC, Tarnawski R, Mandai M, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24(12): 1334–1348.

[241] Lan C, Shen J, Wang Y, Li J, Liu Z, He M, et al. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J Clin Oncol. 2020; 38(34): 4095–4106.

[242] Xia L, Zhou Q, Gao Y, Hu W, Lou G, Sun H, et al. A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma. Nat Commun. 2022; 13(1): 7581.

[243] Wu X, Xia L, Zhang K, Tang Y, Zhang G, Wang D, et al. Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy for recurrent or metastatic cervical cancer. Gynecologic Oncol. 2024; 190: S23–S24.

[244] Yuan L, Shu P, Li X, Li G, Zhang K, Lai L, et al. A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort. J Clin Oncol. 2024; 42(16): 5509.

[245] Oaknin A, Gladieff L, Martinez-Garcia J. Villacampa G, Takekuma M, De Giorgi U, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024; 403(10421): 31–43.

[246] Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022; 72(2): 165–182.

[247] Coleman RL, Lorusso D, Gennigens C, Gonzalez-Martin A. Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(5): 609–619.

[248] Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020; 26(6): 1220–1228.

[249] Vergote I, Gonzalez-Martin A. Fujiwara K, Kalbacher E, Bagameri A, Ghamande S, et al. Tisotumab Vedotin as Second-or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024; 391(1): 44–55.

[250] Vergote I, Van Nieuwenhuysen E, O’Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. J Clin Oncol. 2023; 41(36): 5536–5549.

[251] FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors 2024. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

[252] Itkin B, Garcia A, Straminsky S, Adelchanow ED, Pereyra M, Haab GA, et al. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis. PLoS One. 2021; 16(9): e0257976.

[253] Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A. et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024; 42(1): 47–58.

[254] Li BT, Meric-Bernstam F. Bardia A, Naito Y, Siena S, Aftimos PG, et al. 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Annals Oncol. 2023; 34: S459–S460.

[255] Wu L, Li G, Zhang Y, An R, Sun L, Zhang K, et al. Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study. Int J Gynecol Cancer. 2024; 34: A6.

[256] Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One. 2013; 8(9): e75864.

[257] Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, et al. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Sci Rep. 2020; 10(1): 973.

[258] SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential 2024. Available from: https://www.prnewswire.com/news-releases/sgo-2024–the-first-published-clinical-data-of-nectin-4-targeting-adc-developed-by-mabwell-in-cervical-cancer-demonstrates-its-outstanding-therapeutic-potential-302092792.html

[259] Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348(6230): 62–68.

[260] Ferrall L, Lin KY, Roden RBS, Hung CF, Wu TC. Cervical Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2021; 27(18): 4953–4973.

[261] Zsiros E, Tsuji T, Odunsi K. Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer. J Clin Oncol. 2015; 33(14): 1521–1522.

[262] Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017; 356(6334): 200–205.

[263] Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015; 33(14): 1543–1550.

[264] Zhang Y, Li X, Zhang J, Mao L. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer. Biomed Pharmacother. 2020; 131: 110562.

[265] Long J, Chen X, He M, Ou S, Zhao Y, Yan Q, et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice. Nat Commun. 2024; 15(1): 2271.

[266] Furukawa Y, Ishii M, Ando J, Ikeda K, Igarashi KJ, Kinoshita S, et al. iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer. Cell Rep Med. 2023; 4(12): 101327.

[267] Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Thorac Cancer. 2020; 11(7): 1927–1933.

[268] Plazy C, Hannani D, Gobbini E. Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review. Curr Oncol Rep. 2022; 24(9): 1095–1106.

[269] Perdyan A, Sobocki BK, Balihodzic A, Dabrowska A, Kacperczyk J, Rutkowski J. The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge-A Systematic Review. Cancers (Basel). 2023; 15(13): 3490.

[270] Wang Y, Qiu H, Lin R, Hong W, Lu J, Ling H, et al. Advancements in the Understanding of Small-Cell Neuroendocrine Cervical Cancer: Where We Stand and What Lies Ahead. J Pers Med. 2024; 14(5): 462.

[271] Kawamura M, Koide Y, Murai T, Ishihara S, Takase Y, Murao T, et al. The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments. BMC Cancer. 2021; 21(1): 1046.

[272] Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE, Chen LM, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol. 2010; 203(4):347 e1–6.

[273] Salvo G, Ramalingam P, Flores Legarreta A, Jhingran A, Gonzales NR, Chisholm GB, et al. Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study. Int J Gynecol Cancer. 2021; 31(4): 495–501.

[274] Stecklein SR, Jhingran A, Burzawa J, Ramalingam P, Klopp AH, Eifel PJ, et al. Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol. 2016; 143(3): 552–557.

[275] Tempfer CB, Tischoff I, Dogan A, Hilal Z, Schultheis B, Kern P, et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature. BMC Cancer. 2018; 18(1): 530.

[276] Wang KL, Chang TC, Jung SM, Chen CH, Cheng YM, Wu HH, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer. 2012; 48(10): 1484–1494.

[277] Ishikawa M, Kasamatsu T, Tsuda H, Fukunaga M, Sakamoto A, Kaku T, et al. Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study. Gynecol Oncol. 2018; 148(1): 139–146.

[278] Chu T, Meng Y, Wu P, Li Z, Wen H, Ren F, et al. The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry. Lancet Oncol. 2023; 24(6): 701–708.

[279] Pei X, Xiang L, Ye S, He T, Cheng Y, Yang W, et al. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2017; 147(3): 589–596.

[280] Frumovitz M, Munsell MF, Burzawa JK, Byers LA, Ramalingam P, Brown J, et al. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2017; 144(1): 46–50.

[281] Frumovitz M, Chisholm GB, Jhingran A, Ramalingam P, Flores-Legarreta A. Bhosale P, et al. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study. Am J Obstet Gynecol. 2023; 228(4):445 e1– e8.

[282] Qiu H, Su N, Yan S, Li J. Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study. Technol Cancer Res Treat. 2023; 22: 15330338231160393.

[283] Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019; 9(10): 1372–1387.

[284] Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, et al. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. J Clin Oncol. 2018; 36(16): 1594–1602.

[285] Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, et al. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clin Cancer Res. 2023; 29(2): 331–340.

[286] Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, et al. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol. 2023; 18(4): 517–530.

[287] Carroll MR, Ramalingam P, Salvo G, Fujimoto J, Solis Soto LM, Phoolcharoen N, et al. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int J Gynecol Cancer. 2020; 30(9): 1303–1307.

[288] Wang X, Jia W, Wang M, Liu J, Zhou X, Liang Z, et al. Human papillomavirus integration perspective in small cell cervical carcinoma. Nat Commun. 2022; 13(1): 5968.

[289] Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212): 1929–1939.

[290] Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23): 2220–2229.

[291] Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, et al. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020; 158(3): 570–575.

[292] Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, et al. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017; 22(6): 631–637.

[293] Paterniti TA, Dorr K, Ullah A, White J, Williams H, Ghamande S. Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix. Obstet Gynecol. 2021; 138(5): 813–816.

[294] Paraghamian SE, Longoria TC, Eskander RN. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract. 2017; 4: 3.

[295] Goto S, Terao Y, Kamigaki T, Takimoto R, Naitoh K, Makita K, et al. Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix. Anticancer Res. 2020; 40(8): 4741–4748.

[296] Hodgson A, Olkhov-Mitsel E. Howitt BE, Nucci MR, Parra-Herran C. International Endocervical Adenocarcinoma Criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome. J Clin Pathol. 2019; 72(5): 347–353.

[297] Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, et al. Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis. Am J Surg Pathol. 2015; 39(11): 1449–1457.

[298] Garg S, Nagaria TS, Clarke B, Freedman O, Khan Z, Schwock J, et al. Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. Mod Pathol. 2019; 32(12): 1823–1833.

[299] Park E, Kim SW, Kim S, Kim HS, Lee JY, Kim YT, et al. Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix. Mod Pathol. 2021; 34(3): 637–646.

[300] Kerwin CM, Markese M, Moroney MR, Smith LP, Patel NU. Adenocarcinoma of the uterine cervix, gastric-type (GAS): a review of the literature focused on pathology and multimodality imaging. Abdom Radiol (NY). 2023; 48(2): 713–723.

[301] Kim Y, Kim EY, Kim TJ, Lim KT, Lee KH, Chun Y, et al. A rare case of gastric-type mucinous adenocarcinoma in a woman with Peutz-Jeghers syndrome. Obstet Gynecol Sci. 2019; 62(6): 474–477.

[302] Park SB, Lee JH, Lee YH, Song MJ, Lim KT, Hong SR, et al. Adenoma malignum of the uterine cervix: imaging features with clinicopathologic correlation. Acta Radiol. 2013; 54(1): 113–120.

[303] Kojima A, Shimada M, Mikami Y, Nagao S, Takeshima N, Sugiyama T, et al. Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group. Int J Gynecol Cancer. 2018; 28(1): 99–106.

[304] Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix -An aggressive tumor with a poor prognosis: A multi-institutional study. Gynecol Oncol. 2019; 153(1): 13–19.

[305] Bosse T, Lax S, Abu-Rustum N. Matias-Guiu X. The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2021; 40(Suppl 1): S102–S110.

[306] Shi H, Shao Y, Lu W, Lu B. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification. J Pathol Clin Res. 2021; 7(1): 86–95.

[307] Ehmann S, Sassine D, Straubhar AM, Praiss AM, Aghajanian C, Alektiar KM, et al. Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers. Gynecol Oncol. 2022; 167(3): 458–466.

[308] Nishio H, Matsuda R, Iwata T, Yamagami W. Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions. Jpn J Clin Oncol. 2024; 54(5): 516–520.

[309] Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023; 29(8): 2133–2141.

[310] Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023; 401(10389): 1655–1668.

[311] Zhang L, Ma J, Zhou D, Zhou J, Hu B, Ma X, et al. Single-Nucleus Transcriptome Profiling of Locally Advanced Cervical Squamous Cell Cancer Identifies Neural-Like Progenitor Program Associated with the Efficacy of Radiotherapy. Adv Sci (Weinh). 2023; 10(25): e2300348.

[312] Liu C, Zhang M, Yan X, Ni Y, Gong Y, Wang C, et al. Single-cell dissection of cellular and molecular features underlying human cervical squamous cell carcinoma initiation and progression. Sci Adv. 2023; 9(4): eadd8977.

[313] Cao G, Yue J, Ruan Y, Han Y, Zhi Y, Lu J, et al. Single-cell dissection of cervical cancer reveals key subsets of the tumor immune microenvironment. EMBO J. 2023; 42(16): e110757.

[314] Liu C, Li X, Huang Q, Zhang M, Lei T, Wang F, et al. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer. Signal Transduct Target Ther. 2023; 8(1): 44.

[315] Qiu J, Qu X, Wang Y, Guo C, Lv B, Jiang Q, et al. Single-Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirus-Associate. (HPVA) and Non-HPVA Adenocarcinoma. Adv Sci (Weinh). 2023; 10(10): e2204951.

[316] Qu X, Wang Y, Jiang Q, Ren T, Guo C, Hua K, et al. Interactions of Indoleamine 2, 3-dioxygenase-expressing LAMP3(+) dendritic cells with CD4(+) regulatory T cells and CD8(+) exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications. Cancer Commun (Lond). 2023; 43(11): 1207–1228.

[317] Lin S, Sun Y, Cao C, Zhu Z, Xu Y, Liu B, et al. Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma. EBioMedicine. 2023; 97: 104846.

[318] Song H, Jiang H, Hu W, Hai Y, Cai Y, Li H, et al. Cervical extracellular matrix hydrogel optimizes tumor heterogeneity of cervical squamous cell carcinoma organoids. Sci Adv. 2024; 10(20): eadl3511.

RIGHTS & PERMISSIONS

2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.